Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.

NCT05854641 is registered in ClinicalTrials.gov with Cell Biopeutics Resources Sdn Bhd as lead sponsor.

NCT NCT05854641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05854641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.
Lead sponsor
Cell Biopeutics Resources Sdn Bhd
Phase
Phase 4
Overall status
Recruiting
Start date
January 1, 2024
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, peripheral arterial disease